Liu H, Wu J, Xue S, Zhang Q, Ruan Y, Sun X, Xia S
University Department of Urology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
J Int Med Res. 2013 Aug;41(4):984-92. doi: 10.1177/0300060513477001. Epub 2013 Jun 12.
To compare the safety and efficacy of conventional monopolar transurethral resection of bladder tumour (TURBT) and 2-micron continuous-wave laser resection (2-µm laser) techniques in the management of multiple nonmuscle-invasive bladder cancer (NMIBC), and to investigate long-term effects on tumour recurrence.
Patients with multiple NMIBC were randomized to receive TURBT or 2-µm laser in a nonblinded manner. All patients received intravesical chemotherapy with epirubicin (40 mg/40 ml) for 8 weeks, beginning 1 week after surgery, followed with monthly maintenance therapy for 12 months. Three-year follow-up data of preoperative, operative and postoperative management were recorded.
In total, 120 patients were included: 56 in the TURBT group and 64 in the 2-µm laser group. Intra- and postoperative complications (including bladder perforation, bleeding and irritation) were less frequently observed in the 2-µm laser group compared with the TURBT group. There were no significant differences in first time to recurrence, overall recurrence or occurrence of urethral strictures.
The 2-µm laser resection method was more effective than TURBT in reducing rates of intra- and postoperative complications, but offered no additional benefit regarding tumour recurrence.
比较传统单极经尿道膀胱肿瘤切除术(TURBT)和2微米连续波激光切除术(2-µm激光)治疗多发性非肌层浸润性膀胱癌(NMIBC)的安全性和有效性,并研究其对肿瘤复发的长期影响。
将多发性NMIBC患者以非盲法随机分为接受TURBT或2-µm激光治疗。所有患者在术后1周开始接受表柔比星(40 mg/40 ml)膀胱灌注化疗8周,随后进行为期12个月的每月维持治疗。记录术前、手术及术后管理的三年随访数据。
共纳入120例患者,其中TURBT组56例,2-µm激光组64例。与TURBT组相比,2-µm激光组术中及术后并发症(包括膀胱穿孔、出血和刺激)的发生率较低。首次复发时间、总体复发率或尿道狭窄发生率无显著差异。
2-µm激光切除术在降低术中及术后并发症发生率方面比TURBT更有效,但在肿瘤复发方面没有额外益处。